Avocet Bio GmbH
Avocet Biosciences develops a programmable RNA-targeting therapeutic platform intended to disable RNA viruses by sequence-directed cleavage of viral genomes and transcripts. The organisation focuses on preclinical research, platform design, guide-RNA engineering and translational development toward clinical testing, and collaborates with external partners on technology advancement.
Industries
N/A
Products
Programmable RNA-targeting antiviral platform
A platform that uses sequence-specific guide RNAs and RNA-targeting CRISPR enzymes to cleave viral RNA and inhibit replication, designed for broad-spectrum activity against RNA viruses.
Programmable RNA-targeting antiviral platform
A platform that uses sequence-specific guide RNAs and RNA-targeting CRISPR enzymes to cleave viral RNA and inhibit replication, designed for broad-spectrum activity against RNA viruses.
Services
Collaborative R&D and translational partnerships
Partnership-based research collaborations to advance the programmable RNA-targeting platform and move candidates through preclinical development.
Collaborative R&D and translational partnerships
Partnership-based research collaborations to advance the programmable RNA-targeting platform and move candidates through preclinical development.
Expertise Areas
- RNA-targeting therapeutic development
- CRISPR-based antiviral research
- Preclinical translational research
- Virology and viral genomics
Key Technologies
- RNA-targeting CRISPR systems (Cas13-type)
- Programmable guide RNA design
- In vitro antiviral assay systems
- Platform-based rapid therapeutic prototyping